Results 131 to 140 of about 60,088 (256)

Pathology of the Mediastinal Diseases

open access: yesGüncel Göğüs Hastalıkları Serisi, 2021
openaire   +1 more source

A Case of Acalculous Cholecystitis During Lenvatinib Plus Pembrolizumab Therapy for Advanced Renal Cell Carcinoma

open access: yesIJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction Lenvatinib plus pembrolizumab is a standard first‐line therapy for advanced renal cell carcinoma (RCC), and acute acalculous cholecystitis is a rare adverse event. Case Presentation A 60‐year‐old woman with metastatic TFE3‐positive non–clear cell RCC, classified as poor risk by the International Metastatic RCC Database Consortium (
Erika Soga   +9 more
wiley   +1 more source

Pneumothorax Ex Vacuo

open access: yesJournal of General and Family Medicine, Volume 27, Issue 4, July 2026.
An 84‐year‐old woman with pleural effusion developed anterior chest pain during thoracentesis, and post‐procedural chest radiography revealed hydropneumothorax, initially suggesting iatrogenic pneumothorax. However, comparison of pre‐ and post‐procedure imaging showed ipsilateral hemithoracic volume loss with tracheal deviation toward the procedure ...
Yusuke Ito
wiley   +1 more source

Diagnostic yield and histopathological assessment of endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy: a prospective comparison of two tunnelling approaches. [PDF]

open access: yesERJ Open Res
Oruqaj G   +9 more
europepmc   +1 more source

A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma

open access: yesMedComm, Volume 7, Issue 7, July 2026.
This phase II trial suggests the potential of perioperative camrelizumab plus neoadjuvant chemotherapy in patients with resectable stage IIB‐IIIB lung squamous cell carcinoma. The major pathological response rate (primary endpoint) was 60.0%, and the pathological complete response (pCR) rate was 44.4%.
Mingming Hu   +17 more
wiley   +1 more source

Clinical Remission of an Unresectable Presumptive Haemangiosarcoma in a Dog Treated With Toceranib, Piroxicam, and Propranolol: A Case Report

open access: yesVeterinary Medicine and Science, Volume 12, Issue 4, July 2026.
Radiographic remission of a presumptive unresectable haemangiosarcoma treated with toceranib, piroxicam, and propranolol. In a dog with ACVIM Stage B2 myxomatous mitral valve disease where doxorubicin‐based chemotherapy was contraindicated, this multimodal regimen achieved marked tumour reduction and radiographic disappearance.
Woo Dae Park
wiley   +1 more source

Home - About - Disclaimer - Privacy